Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Capital Expenditures (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Capital Expenditures for 16 consecutive years, with -$5.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 521.73% to -$5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $666000.0, a 91.39% decrease, with the full-year FY2025 number at $666000.0, down 91.39% from a year prior.
  • Capital Expenditures was -$5.5 million for Q4 2025 at Anika Therapeutics, down from $5.4 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $5.4 million in Q3 2025 to a low of -$5.5 million in Q4 2025.
  • A 5-year average of $697500.0 and a median of $1.3 million in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: plummeted 991.09% in 2021, then soared 1359.74% in 2022.
  • Anika Therapeutics' Capital Expenditures stood at -$4.0 million in 2021, then decreased by 21.19% to -$4.8 million in 2022, then soared by 196.47% to $4.7 million in 2023, then tumbled by 72.06% to $1.3 million in 2024, then plummeted by 521.73% to -$5.5 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Capital Expenditures are -$5.5 million (Q4 2025), $5.4 million (Q3 2025), and -$2.0 million (Q2 2025).